Weight loss-independent mechanism to ameliorate osteoarthritis by semaglutide
Occurrence and progression of osteoarthritis (OA) is linked to metabolic disorders but molecular mechanism is not clear.
The researchers in this study demonstrate chondroprotective effects of a glucagon-like peptide-1 receptor (GLP-1R) agonist, semaglutide, in obesity-related osteoarthritis.
Mechanistically, these effects are independent of body weight loss and involve metabolic reprogramming of chondrocyte via the GLP-1R-AMPKPFKFB3 signaling axis.
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00008-2
https://sciencemission.com/Semaglutide-ameliorates-osteoarthritis
